A new study reveals the significant utility of real-time navigation in aiding surgeons during ablation procedures targeted at liver tumours.
This is according to fresh research that sheds light on a promising advancement in cancer treatment methodology.
The study, conducted at the University of Cincinnati Cancer Centre and led by Dr David A Gerber, MD, was recently published in JAMA Network.
Ablation is usually suitable for small- to medium-sized tumours, offering a less invasive alternative to surgical removal.
Liver cancer is the fourth-leading cause of cancer-related deaths globally.
This underlines the urgency for innovative approaches such as ablation.
Traditionally, surgeons have relied on two-dimensional ultrasound guidance for tumour localisation during ablation procedures despite the process’s inherently three-dimensional nature.
Dr Gerber likens this to navigating a 3D space using only a 2D map, highlighting the challenge surgeons face in visualising all dimensions simultaneously.
The study introduces a game-changing technology providing 3D navigation alongside static ultrasound imaging.
Surgeons can access real-time augmented reality images by employing an electromagnetic field generator and spatial sensors, offering precise tumour localisation information.
This enhancement significantly aids in navigating complex anatomical structures, improving procedural accuracy and efficacy.
In a retrospective analysis comparing over 750 ablation procedures conducted by a single experienced surgeon, both with and without navigation, between June 2011 and January 2021, the study found no statistically significant differences in survival rates or rates of incomplete ablations.
Notably, the navigation group included more patients with advanced disease and tumours in challenging anatomical locations.
Dr Gerber emphasises the potential of real-time navigation as a valuable adjunct for surgeons performing liver cancer ablations, particularly for those with limited experience in intraoperative targeting.
While experienced surgeons may not experience as pronounced benefits, the technology holds immense promise in accelerating the learning curve for less seasoned practitioners.
He said: ‘Incorporating ablation into clinical practice is still very new, and most surgeons will have little to no experience with intraoperative targeting. This clinical experience is one of the largest in North America, so navigation will likely have a greater impact for the less experienced surgeon.’
Dr Gerber said technological innovations are key to helping most surgeons adopt new treatments and procedures like ablation. ‘This technology allowed me as an experienced provider to teach a less experienced provider rapidly, and the navigation accelerates their time to proficiency.’
Technological innovations are pivotal in facilitating the adoption of novel treatments like ablation among surgeons.
Dr Gerber underscored the significance of such advancements in empowering experienced and novice providers alike, ultimately advancing the standard of care in liver cancer treatment.
